JP2024543931A5 - - Google Patents
Info
- Publication number
- JP2024543931A5 JP2024543931A5 JP2024531530A JP2024531530A JP2024543931A5 JP 2024543931 A5 JP2024543931 A5 JP 2024543931A5 JP 2024531530 A JP2024531530 A JP 2024531530A JP 2024531530 A JP2024531530 A JP 2024531530A JP 2024543931 A5 JP2024543931 A5 JP 2024543931A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- concentration
- seq
- approximately
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111462784.6 | 2021-11-30 | ||
| CN202111462784 | 2021-11-30 | ||
| PCT/CN2022/135247 WO2023098694A1 (zh) | 2021-11-30 | 2022-11-30 | 一种抗sost抗体药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543931A JP2024543931A (ja) | 2024-11-26 |
| JP2024543931A5 true JP2024543931A5 (enExample) | 2025-12-05 |
Family
ID=86611532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531530A Pending JP2024543931A (ja) | 2021-11-30 | 2022-11-30 | 抗ｓｏｓｔ抗体医薬組成物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250011411A1 (enExample) |
| EP (1) | EP4434517A4 (enExample) |
| JP (1) | JP2024543931A (enExample) |
| CN (1) | CN118175993A (enExample) |
| AU (1) | AU2022401939A1 (enExample) |
| CA (1) | CA3238868A1 (enExample) |
| TW (1) | TW202330032A (enExample) |
| WO (1) | WO2023098694A1 (enExample) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2011126338A (ru) * | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
| AR075715A1 (es) * | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| HK1200322A1 (en) * | 2011-10-24 | 2015-08-07 | Abbvie Inc. | Immunobinders directed against sclerostin |
| SI3269735T1 (sl) | 2015-03-13 | 2020-12-31 | Jiangsu Hengrui Medicine Co. Ltd. | Protitelo proti sklerostinu, antigen-vezavni fragment in medicinska uporaba le-tega |
| GB201604124D0 (en) * | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| CN109952093B (zh) | 2017-07-27 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | 一种sost抗体药物组合物及其用途 |
| EP4013786A1 (en) * | 2019-08-12 | 2022-06-22 | Amgen Inc. | Anti-sclerostin antibody formulations |
-
2022
- 2022-11-30 EP EP22900498.1A patent/EP4434517A4/en active Pending
- 2022-11-30 WO PCT/CN2022/135247 patent/WO2023098694A1/zh not_active Ceased
- 2022-11-30 CA CA3238868A patent/CA3238868A1/en active Pending
- 2022-11-30 US US18/713,590 patent/US20250011411A1/en active Pending
- 2022-11-30 TW TW111145967A patent/TW202330032A/zh unknown
- 2022-11-30 CN CN202280072603.5A patent/CN118175993A/zh active Pending
- 2022-11-30 JP JP2024531530A patent/JP2024543931A/ja active Pending
- 2022-11-30 AU AU2022401939A patent/AU2022401939A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI689517B (zh) | 高濃度抗體製劑 | |
| JP2024016177A5 (enExample) | ||
| JP2024506940A5 (enExample) | ||
| JP7046088B2 (ja) | 抗ｒｓｖモノクローナル抗体製剤 | |
| JP2023515271A5 (enExample) | ||
| JP2024508762A5 (enExample) | ||
| JP2020518599A5 (enExample) | ||
| JP2022532927A5 (enExample) | ||
| JP2020518598A5 (enExample) | ||
| JP2010511665A5 (enExample) | ||
| JP2016534052A5 (enExample) | ||
| RU2012131099A (ru) | Препарат антитела | |
| JP2020509031A5 (enExample) | ||
| MY182680A (en) | Antibody formulation and therapeutic regimens | |
| CN109952093A (zh) | 一种sost抗体药物组合物及其用途 | |
| JP2022512704A5 (enExample) | ||
| JP2024540377A5 (enExample) | ||
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| JP2024540395A5 (enExample) | ||
| JP2024518536A5 (enExample) | ||
| JP2024543931A5 (enExample) | ||
| JP2022519796A5 (enExample) | ||
| JP2024508746A5 (enExample) | ||
| RU2779430C2 (ru) | Фармацевтическая композиция, содержащая антитело к sost, и ее применения | |
| JP2025502861A5 (enExample) |